Technologies to Assess Drug Response and Heterogeneity in Patient-Derived Cancer Organoids

Literature Cited

1. 1.

   Collins A, Miles GJ, Wood J, MacFarlane M, Pritchard C, Moss E 2020. Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer. Gynecol. Oncol. 156:251–59
   [Google Scholar]
2. 2.

   Huo K-G, D'Arcangelo E, Tsao M-S 2020. Patient-derived cell line, xenograft and organoid models in lung cancer therapy. Transl. Lung Cancer Res. 9:2214–32
   [Google Scholar]
3. 3.

   Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A. 2019. Current and future horizons of patient-derived xenograft models in colorectal cancer translational research. Cancers 11:1321
   [Google Scholar]
4. 4.

   Castro F, Pereira CL, Macedo MH, Almeida A, Silveira MJ et al. 2021. Advances on colorectal cancer 3D models: the needed translational technology for nanomedicine screening. Adv. Drug Deliv. Rev. 175:113824
   [Google Scholar]
5. 5.

   Driehuis E, Kretzschmar K, Clevers H. 2020. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15:3380–409
   [Google Scholar]
6. 6.

   Dekkers JF, Alieva M, Wellens LM, Ariese HC, Jamieson PR et al. 2019. High-resolution 3D imaging of fixed and cleared organoids. Nat. Protoc. 14:1756–71
   [Google Scholar]
7. 7.

   Kratochvil MJ, Seymour AJ, Li TL, Paşca SP, Kuo CJ, Heilshorn SC. 2019. Engineered materials for organoid systems. Nat. Rev. Mater. 4:606–22
   [Google Scholar]
8. 8.

   Driehuis E, Kolders S, Spelier S, Lõhmussaar K, Willems SM et al. 2019. Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discov 9:852–71
   [Google Scholar]
9. 9.

   Ganesh K, Wu C, O'Rourke KP, Szeglin BC, Zheng Y et al. 2019. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat. Med. 25:1607–14
   [Google Scholar]
10. 10.

    Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S et al. 2019. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Translational Med. 11:eaay2574
    [Google Scholar]
11. 11.

    Sharick JT, Walsh CM, Sprackling CM, Pasch CA, Pham DL et al. 2020. Metabolic heterogeneity in patient tumor-derived organoids by primary site and drug treatment. Front. Oncol. 10:553
    [Google Scholar]
12. 12.

    Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A et al. 2018. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov 8:1112–29
    [Google Scholar]
13. 13.

    Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J et al. 2018. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359:920–26
    [Google Scholar]
14. 14.

    Yao Y, Xu X, Yang L, Zhu J, Wan J et al. 2020. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26:17–26.e6
    [Google Scholar]
15. 15.

    Lou Y-R, Leung AW. 2018. Next generation organoids for biomedical research and applications. Biotechnol. Adv. 36:132–49
    [Google Scholar]
16. 16.

    Wensink GE, Elias SG, Mullenders J, Koopman M, Boj SF et al. 2021. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precision Oncol 5:30
    [Google Scholar]
17. 17.

    Kondo J, Inoue M. 2019. Application of cancer organoid model for drug screening and personalized therapy. Cells 8:470
    [Google Scholar]
18. 18.

    LeSavage BL, Suhar RA, Broguiere N, Lutolf MP, Heilshorn SC. 2021. Next-generation cancer organoids. Nat. Mater. 21:143–59
    [Google Scholar]
19. 19.

    Drost J, Clevers H. 2018. Organoids in cancer research. Nat. Rev. Cancer 18:407–18
    [Google Scholar]
20. 20.

    Tuveson D, Clevers H. 2019. Cancer modeling meets human organoid technology. Science 364:952–55
    [Google Scholar]
21. 21.

    Pasch CA, Favreau PF, Yueh AE, Babiarz CP, Gillette AA et al. 2019. Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clin. Cancer Res. 25:5376–87
    [Google Scholar]
22. 22.

    Dijkstra KK, Monkhorst K, Schipper LJ, Hartemink KJ, Smit EF et al. 2020. Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. Cell Rep 31:107588
    [Google Scholar]
23. 23.

    Gillette AA, Babiarz CP, VanDommelen AR, Pasch CA, Clipson L et al. 2021. Autofluorescence imaging of treatment response in neuroendocrine tumor organoids. Cancers 13:1873
    [Google Scholar]
24. 24.

    van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F et al. 2015. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161:933–45
    [Google Scholar]
25. 25.

    Kondo J, Endo H, Okuyama H, Ishikawa O, Iishi H et al. 2011. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. PNAS 108:6235–40
    [Google Scholar]
26. 26.

    Arnadottir SS, Jeppesen M, Lamy P, Bramsen JB, Nordentoft I et al. 2018. Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patient-derived spheroid cultures. Mol. Oncol. 12:132–47
    [Google Scholar]
27. 27.

    Weeber F, van de Wetering M, Hoogstraat M, Dijkstra KK, Krijgsman O et al. 2015. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. PNAS 112:13308–11
    [Google Scholar]
28. 28.

    Sato T, Stange DE, Ferrante M, Vries RG, van Es JH et al. 2011. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141:1762–72
    [Google Scholar]
29. 29.

    Kopper O, De Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N et al. 2019. An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity. Nat. Med. 25:838–49
    [Google Scholar]
30. 30.

    Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM et al. 2017. Human primary liver cancer–derived organoid cultures for disease modeling and drug screening. Nat. Med. 23:1424–35
    [Google Scholar]
31. 31.

    Boj SF, Hwang C-I, Baker LA, Chio IIC, Engle DD et al. 2015. Organoid models of human and mouse ductal pancreatic cancer. Cell 160:324–38
    [Google Scholar]
32. 32.

    Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G et al. 2018. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172:373–86.e10
    [Google Scholar]
33. 33.

    Turco MY, Gardner L, Hughes J, Cindrova-Davies T, Gomez MJ et al. 2017. Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium. Nat. Cell Biol. 19:568–77
    [Google Scholar]
34. 34.

    Schutgens F, Rookmaaker MB, Margaritis T, Rios A, Ammerlaan C et al. 2019. Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nat. Biotechnol. 37:303–13
    [Google Scholar]
35. 35.

    Larsen BM, Kannan M, Langer LF, Leibowitz BD, Bentaieb A et al. 2021. A pan-cancer organoid platform for precision medicine. Cell Rep 36:109429
    [Google Scholar]
36. 36.

    Tsai S, McOlash L, Palen K, Johnson B, Duris C et al. 2018. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer 18:1335
    [Google Scholar]
37. 37.

    Francies HE, Barthorpe A, McLaren-Douglas A, Barendt WJ, Garnett MJ. 2016. Drug sensitivity assays of human cancer organoid cultures. Organoids K Turksen 339–51 New York: Humana
    [Google Scholar]
38. 38.

    Hu Y, Sui X, Song F, Li Y, Li K et al. 2021. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat. Commun. 12:2581
    [Google Scholar]
39. 39.

    Seppälä TT, Zimmerman JW, Sereni E, Plenker D, Suri R et al. 2020. Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer. Ann. Surg. 272:427–35
    [Google Scholar]
40. 40.

    Zoetemelk M, Rausch M, Colin DJ, Dormond O, Nowak-Sliwinska P. 2019. Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma. Sci. Rep. 9:7103
    [Google Scholar]
41. 41.

    Hafner M, Niepel M, Chung M, Sorger PK 2016. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13:521–27
    [Google Scholar]
42. 42.

    Zack GW, Rogers WE, Latt SA. 1977. Automatic measurement of sister chromatid exchange frequency. J. Histochem. Cytochem. 25:741–53
    [Google Scholar]
43. 43.

    Walton W. 1948. Feret's statistical diameter as a measure of particle size. Nature 162:329–30
    [Google Scholar]
44. 44.

    Batlle E, Clevers H. 2017. Cancer stem cells revisited. Nat. Med. 23:1124–34
    [Google Scholar]
45. 45.

    Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G et al. 2014. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res 74:5184–94
    [Google Scholar]
46. 46.

    Shah AT, Diggins KE, Walsh AJ, Irish JM, Skala MC. 2015. In vivo autofluorescence imaging of tumor heterogeneity in response to treatment. Neoplasia 17:862–70
    [Google Scholar]
47. 47.

    Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A et al. 2013. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res 73:6164–74
    [Google Scholar]
48. 48.

    Shah AT, Heaster TM, Skala MC. 2017. Metabolic imaging of head and neck cancer organoids. PLOS ONE 12:e0170415
    [Google Scholar]
49. 49.

    Walsh AJ, Cook RS, Skala MC. 2017. Functional optical imaging of primary human tumor organoids: development of a personalized drug screen. J. Nucl. Med. 58:1367–72
    [Google Scholar]
50. 50.

    Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC. 2016. Drug response in organoids generated from frozen primary tumor tissues. Sci. Rep. 6:18889
    [Google Scholar]
51. 51.

    Walsh AJ, Mueller KP, Tweed K, Jones I, Walsh CM et al. 2021. Classification of T-cell activation via autofluorescence lifetime imaging. Nat. Biomed. Eng. 5:77–88
    [Google Scholar]
52. 52.

    Chance B, Schoener B, Oshino R, Itshak F, Nakase Y. 1979. Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. J. Biol. Chem. 254:4764–71
    [Google Scholar]
53. 53.

    Georgakoudi I, Quinn KP. 2012. Optical imaging using endogenous contrast to assess metabolic state. Annu. Rev. Biomed. Eng. 14:351–67
    [Google Scholar]
54. 54.

    Alhallak K, Rebello LG, Muldoon TJ, Quinn KP, Rajaram N. 2016. Optical redox ratio identifies metastatic potential-dependent changes in breast cancer cell metabolism. Biomed. Opt. Express 7:4364–74
    [Google Scholar]
55. 55.

    Lakowicz JR, Szmacinski H, Nowaczyk K, Johnson ML. 1992. Fluorescence lifetime imaging of free and protein-bound NADH. PNAS 89:1271–75
    [Google Scholar]
56. 56.

    Sharick JT, Favreau PF, Gillette AA, Sdao SM, Merrins MJ, Skala MC. 2018. Protein-bound NAD(P)H lifetime is sensitive to multiple fates of glucose carbon. Sci. Rep. 8:5456
    [Google Scholar]
57. 57.

    Becker W. 2014. The bh TCSPC Handbook Berlin: Becker & Hickl
58. 58.

    Sharick JT, Jeffery JJ, Karim MR, Walsh CM, Esbona K et al. 2019. Cellular metabolic heterogeneity in vivo is recapitulated in tumor organoids. Neoplasia 21:615–26
    [Google Scholar]
59. 59.

    Walsh A, Cook RS, Rexer B, Arteaga CL, Skala MC. 2012. Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Biomed. Opt. Express 3:75–85
    [Google Scholar]
60. 60.

    Walsh AJ, Castellanos JA, Nagathihalli NS, Merchant NB, Skala MC. 2016. Optical imaging of drug-induced metabolism changes in murine and human pancreatic cancer organoids reveals heterogeneous drug response. Pancreas 45:863–69
    [Google Scholar]
61. 61.

    Hedges LV. 1981. Distribution theory for Glass's estimator of effect size and related estimators. J. Educ. Stat. 6:107–28
    [Google Scholar]
62. 62.

    Gil DA, Deming DA, Skala MC. 2021. Patient-derived cancer organoid tracking with wide-field one-photon redox imaging to assess treatment response. J. Biomed. Opt. 26:036005
    [Google Scholar]
63. 63.

    Dagogo-Jack I, Shaw AT 2018. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15:81–94
    [Google Scholar]
64. 64.

    Vitale I, Shema E, Loi S, Galluzzi L. 2021. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27:212–24
    [Google Scholar]
65. 65.

    Kim J, DeBerardinis RJ. 2019. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab 30:434–46
    [Google Scholar]
66. 66.

    Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl. . J. Med. 366:883–92
    [Google Scholar]
67. 67.

    Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D et al. 2018. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov 8:164–73
    [Google Scholar]
68. 68.

    Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Ng AWT et al. 2020. The repertoire of mutational signatures in human cancer. Nature 578:94–101
    [Google Scholar]
69. 69.

    Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. 2013. Cancer genome landscapes. Science 339:1546–58
    [Google Scholar]
70. 70.

    Swanton C. 2012. Intratumor heterogeneity: evolution through space and time. Cancer Res 72:4875–82
    [Google Scholar]
71. 71.

    Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP et al. 2015. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47:209–16
    [Google Scholar]
72. 72.

    Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB et al. 2018. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 173:515–28.e17
    [Google Scholar]
73. 73.

    Yan HH, Siu HC, Law S, Ho SL, Yue SS et al. 2018. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell 23:882–97.e11
    [Google Scholar]
74. 74.

    Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG et al. 2018. A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clin. Cancer Res. 24:4332–45
    [Google Scholar]
75. 75.

    Jacob F, Salinas RD, Zhang DY, Nguyen PT, Schnoll JG et al. 2020. A patient-derived glioblastoma organoid model and biobank recapitulates inter-and intra-tumoral heterogeneity. Cell 180:188–204.e22
    [Google Scholar]
76. 76.

    Jiang S, Zhao H, Zhang W, Wang J, Liu Y et al. 2020. An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity. Cell Rep. Med. 1:100161
    [Google Scholar]
77. 77.

    Li L, Knutsdottir H, Hui K, Weiss MJ, He J et al. 2019. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight 4:e121490
    [Google Scholar]
78. 78.

    Calandrini C, Schutgens F, Oka R, Margaritis T, Candelli T et al. 2020. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nat. Commun. 11:1310
    [Google Scholar]
79. 79.

    Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B et al. 2019. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat. Cell Biol. 21:1041–51
    [Google Scholar]
80. 80.

    DeStefanis RA, Olson AM, DeZeeuw AK, Gillette AA, Sha GC et al. 2021. Impact of baseline culture conditions of mouse-derived cancer organoids when determining therapeutic response and tumor heterogeneity. bioRxiv 2021.10.12.464087. https://doi.org/10.1101/2021.10.12.464087
    [Crossref]
81. 81.

    Kratz JD, Rehman S, Johnson KA, Gillette AA, Sunil A et al. 2021. Integrating subclonal response heterogeneity to define cancer organoid therapeutic sensitivity. bioRxiv 2021.10.15.464556. https://doi.org/10.1101/2021.10.15.464556
    [Crossref]
82. 82.

    Saito T, Niida A, Uchi R, Hirata H, Komatsu H et al. 2018. A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. Nat. Commun. 9:2884
    [Google Scholar]
83. 83.

    Bollen Y, Stelloo E, van Leenen P, van den Bos M, Ponsioen B et al. 2021. Reconstructing single-cell karyotype alterations in colorectal cancer identifies punctuated and gradual diversification patterns. Nat. Genet. 53:1187–95
    [Google Scholar]
84. 84.

    Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J et al. 2018. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174:1586–98.e12
    [Google Scholar]
85. 85.

    Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL et al. 2018. Organoid modeling of the tumor immune microenvironment. Cell 175:1972–88.e16
    [Google Scholar]
86. 86.

    Shelton SE, Nguyen HT, DA Barbie, Kamm RD. 2020. Engineering approaches for studying immune-tumor cell interactions and immunotherapy. iScience 24:101985
    [Google Scholar]
87. 87.

    Ayuso JM, Rehman S, Virumbrales-Munoz M, McMinn PH, Geiger P et al. 2021. Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion. Sci. Adv. 7:eabc2331
    [Google Scholar]
88. 88.

    Tsai S, McOlash L, Palen K, Johnson B, Duris C et al. 2018. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer 18:335
    [Google Scholar]
89. 89.

    Rodriguez AD, Horowitz LF, Castro K, Kenerson H, Bhattacharjee N et al. 2020. A microfluidic platform for functional testing of cancer drugs on intact tumor slices. . Lab Chip 20:91658–75
    [Google Scholar]
90. 90.

    He K, Gkioxari G, Dollár P, Girshick R. 2017. Mask R-CNN. Proceedings of the IEEE International Conference on Computer Vision, 20172961–69 New York: IEEE
    [Google Scholar]
91. 91.

    DeZeeuw AK, DeStefanis RA, Sha G, Pasch CA, Clipson L, Deming DA. 2020. Murine-derived colorectal cancer organoid culture high-throughput drug screening to identify novel combinations targeting PIK3CA mutant cancers. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020 Abstract 3048 Philadelphia: AACR
    [Google Scholar]
92. 92.

    Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D et al. 2017. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun. 8:14262
    [Google Scholar]
93. 93.

    Narasimhan V, Wright JA, Churchill M, Wang T, Rosati R et al. 2020. Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy. Clin. Cancer Res. 26:3662–70
    [Google Scholar]